{"id":"W3159728738","doi":"10.1038/s41467-021-22582-6","title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lawson Health Research Institute; Université de Montréal; Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development; National Cancer Institute; Stand Up To Cancer; Genentech; Foundation Medicine; Sierra Oncology; PharmaMar; AstraZeneca Australia; Eisai; Mateon Therapeutics; National Breast Cancer Foundation; BeiGene; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; Ludwig Institute for Cancer Research; Exelixis; Eli Lilly and Company; U.S. Department of Defense; Sanofi; GlaxoSmithKline; Ovarian Cancer Research Fund; Bristol-Myers Squibb; AstraZeneca; Pfizer; Ovarian Cancer Research Fund Alliance; Array BioPharma","keywords":"Cancer research; PARP inhibitor; Ovarian cancer; Medicine; Biomarker; Oncology; Homologous recombination; Biology; Bioinformatics; Cancer; Internal medicine; Poly ADP ribose polymerase; Genetics; Gene; Polymerase","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001315708,0.0002676882,0.0004512293,0.0002771325,0.0001751078,0.0005527267,0.0003806095,0.0005700426,0.002839547],"category_scores_gemma":[0.001611503,0.0002153889,0.0003993393,0.0002326041,0.00028966,0.0004801764,0.0002169357,0.0008949345,0.0004397365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003282565,"about_ca_system_score_gemma":0.0003901766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005867206,"about_ca_topic_score_gemma":0.001384789,"domain_scores_codex":[0.9996376,0.0001426347,0.00002473009,0.00007120144,0.00004485008,0.00007899717],"domain_scores_gemma":[0.9990959,0.0002911123,0.0001966662,0.00007993985,0.0000497002,0.0002867543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1669309,0.006932671,0.6830564,0.0001257818,0.0008650568,0.0004566779,0.0001847327,0.001656575,0.04759869,0.0003553248,0.002624192,0.08921301],"study_design_scores_gemma":[0.005417742,0.03505514,0.9498502,0.00001245829,0.0003364115,0.0005852422,0.00009012729,0.002422052,0.003353826,0.0002369629,0.002612536,0.00002719601],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9987864,0.0002161145,0.00008688428,0.00006629371,0.000007135086,0.00003475747,0.0003046171,0.000008963677,0.0004888937],"genre_scores_gemma":[0.997895,0.00007720884,0.0001842055,0.00008377415,0.00002368753,0.00005368944,0.0008638898,0.000005074503,0.0008134517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002839547,"threshold_uncertainty_score":0.009499192,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06698202711603134,"score_gpt":0.4452275900725575,"score_spread":0.3782455629565262,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}